Treating patients with Crohn's disease with biologics early on instead of after treatment with corticosteroids or thiopurines resulted in better outcomes, according to a study led by Ryan Ungaro, MD, of the Icahn School of Medicine at Mount Sinai that was published in Alimentary Pharmacology and Therapeutics. Patients who received biologics early had lower relapse rates, higher mucosal healing scores and higher remission rates, the study found.
Early biologic use could lead to better Crohn's outcomes
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.